Building a Hepatocyte Lipid Droplet Model

Steatosis and lipotoxicity use the same reagents in different ratios.

Choose the cell before the protocol

CellDoubling timeLipid loadingUse when
HepG2~30 hEfficient, but glycolyticScreening; not for insulin or gluconeogenesis claims
Huh7~24 hEfficient, heterogeneousReporter assays; avoid for metabolic flux
Primary human hepatocyteNon-dividingEfficient, physiologicalShort-term mechanism; ≤ 72 h
iPSC-derived hepatocyteNon-dividingModerate; varies by protocolGenotype-defined questions
HepG2/Huh7 in 3D—Higher, with polaritySecretion and architecture

Caveat on HepG2. The line is a hepatoblastoma derivative with low albumin, low CYP and a glycolytic phenotype. It loads lipid readily, which makes it convenient and misleading: the loading is a property of a proliferating tumour line, not of a hepatocyte. Any claim about hepatocyte lipid handling — export, oxidation, very-low-density lipoprotein assembly — should be confirmed in a model that performs those functions.

The fatty acid composition

CompositionTotal FAStorageInjuryModels
Oleate only200–400 µMHighLowSteatosis
Palmitate only100–400 µMLow–moderateHighLipotoxicity
Oleate : palmitate 2:1200–400 µMHighModerateCommon MASH induction
Oleate : palmitate 1:1200–400 µMModerateHigherInjury-weighted
+ free cholesterol20–50 µg/mL with FACholesterol crystalsInflammasomeSpecific sub-phenotype

Oleate is efficiently esterified into triglyceride and stored in large droplets. Palmitate enters the same pathway but exceeds the esterification capacity relative to its flux, so it is routed to ceramide, diacylglycerol and ER stress. Adding oleate therefore increases triglyceride and reduces palmitate toxicity — the paradox the disease pillar describes, reproducible in a well.

Important distinction. A protocol using palmitate alone is a lipotoxicity model, and calling it a steatosis model inverts the result: the lipid content may be lower than in the oleate condition while the injury is higher.

Conjugation and delivery

  1. Dissolve sodium oleate and sodium palmitate separately in water at 70 °C, or in ethanol at 0.1 M stock.
  2. Add dropwise to fatty-acid-free BSA (10–15% w/v in PBS) at 37 °C with stirring.
  3. Adjust to a 3:1–6:1 fatty acid : BSA molar ratio.
  4. Cool, filter 0.22 µm, and use within a week; freeze aliquots at −20 °C.
  5. Add to medium to reach the target total fatty acid concentration; do not exceed 1% v/v of vehicle.
ParameterWhy it matters
FA-free BSAResidual fatty acids dominate at low palmitate
Molar ratioSets the free (unbound) concentration, which is the active fraction
FiltrationCrystals are phagocytosed and produce artefactual effects
Vehicle matchedEthanol and BSA both change baseline lipid handling

Caveat on "200 µM palmitate". Two laboratories using that nominal concentration at different BSA ratios can differ several fold in free palmitate. The ratio, not the concentration, is the variable to report.

Timing and refresh

DayManipulationReadout
−1Seed to 70–80% confluence—
0Add fatty acids in low-serum medium (1–2% FBS)Baseline lipid
1Refresh fatty acidsLipid accumulation
2Readout: lipid, viability, injurySteatosis established
3–4Extended exposureInjury and ER stress
5+Co-culture with stellate cellsActivation markers

Loading saturates. In most protocols triglyceride peaks at 48–72 h and then plateaus or falls as lipotoxicity reduces cell number. A 96-hour timepoint is therefore not "more steatosis"; it is a different population.

Readout note. Normalise lipid to cell number or DNA, not to well. A condition with 30% fewer cells can show less lipid per well and more per cell, and the two conclusions are opposite.

Readouts and their timing

ReadoutEarliest changeConfounder
BODIPY area per cell12–24 hDroplet size versus number
Triglyceride mass24 hEsterification only
Lipid species (DAG, ceramide)24–48 hRequires mass spectrometry
LDH release24–48 hNecrosis and apoptosis both
Caspase-3/724–48 hDoes not exclude other programmes
CHOP / XBP1s12–24 hResponse, not death
Albumin secretionFalls with dedifferentiationNot a lipid readout
ApoB / triglyceride secretion24–48 hThe retention measurement

Important distinction. Retention is the disease-relevant quantity: lipid accumulates when uptake and synthesis exceed export and oxidation. A model that increases triglyceride without measuring export has shown accumulation, not retention.

QC gates

A model is usable if all four pass:

  1. Differentiation state — albumin and, where relevant, CYP expression at the time of treatment.
  2. Loading efficiency — ≥ 70% of cells with visible droplets; report the distribution, not a representative image.
  3. Viability — ≥ 85% at the readout timepoint, otherwise the lipid value is a surviving-subpopulation value.
  4. Vehicle equivalence — BSA- and ethanol-matched controls show no lipid accumulation.

Failing gate 3 is the most common reason a "steatosis model" is actually a selection experiment.

Failures that recur

  • • Palmitate-only protocol labelled steatosis.
  • • Triglyceride as the efficacy endpoint — it can fall while DAG and free cholesterol rise.
  • • No cell-number normalisation.
  • • Lipid readout by representative image only. Quantify per cell, with a distribution.
  • • BSA ratio unreported.
  • • Long exposure with falling viability read as increased steatosis.
  • • Fibrosis claimed from a monoculture. There are no stellate cells.

Where this connects

  • • MASH cell models article supplies the compartment and cell-choice logic.
  • • Lipid pillar supplies the species and esterification rules.
  • • Disease pillar supplies the readout frame: steatosis, activity and fibrosis are separate claims.
  • • Palmitate handling at the biophysical level is treated in the lipid-pillar article on palmitate and BSA.

Scientific interpretation and experimental design

  • • The ratio is the model. Oleate stores, palmitate injures.
  • • Report free fatty acid exposure. Ratio plus concentration.
  • • Normalise to cells, not wells.
  • • Check viability at the readout. Otherwise it is a selection experiment.
  • • Measure export to claim retention.
  • • Quantify droplets as a distribution.
  • • Stop at the compartment boundary. No stellate cells, no fibrosis claim.

Selected references for further reading

  • • Ricchi M, et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. Journal of Gastroenterology and Hepatology. 2009;24:830–840.
  • • Listenberger LL, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. PNAS. 2003;100:3077–3082.
  • • Gómez-Lechón MJ, et al. A human hepatocellular in vitro model to investigate steatosis. Chemico-Biological Interactions. 2007;165:106–116.
  • • Friedman SL, et al. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018;24:908–922.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: